See more : Questback Group AS (QUEST.OL) Income Statement Analysis – Financial Results
Complete financial analysis of Evaxion Biotech A/S (EVAX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evaxion Biotech A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shenzhen Glory Medical Co.,Ltd. (002551.SZ) Income Statement Analysis – Financial Results
- XTGLOBAL INFOTECH LIMITED (XTGLOBAL.BO) Income Statement Analysis – Financial Results
- Green Block Mining Corp. (LGLOF) Income Statement Analysis – Financial Results
- Unity Biotechnology, Inc. (UBX) Income Statement Analysis – Financial Results
- AG Mortgage Investment Trust, I (MITN) Income Statement Analysis – Financial Results
Evaxion Biotech A/S (EVAX)
About Evaxion Biotech A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 73.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 112.00 | 571.32K | 343.45K | 105.72K | 80.98K | 73.93K |
| Gross Profit | 72.89K | -571.32K | -343.45K | -105.72K | -80.98K | -73.93K |
| Gross Profit Ratio | 99.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.92M | 17.06M | 19.58M | 10.90M | 8.22M | 3.73M |
| General & Administrative | 10.35M | 8.21M | 6.25M | 5.67M | 2.63M | 1.88M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.35M | 8.21M | 6.25M | 5.67M | 2.63M | 1.88M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 16.00K | 15.00K |
| Operating Expenses | 22.25M | 25.26M | 25.83M | 16.57M | 10.86M | 5.63M |
| Cost & Expenses | 22.27M | 25.26M | 25.83M | 16.57M | 10.86M | 5.63M |
| Interest Income | 154.00K | 2.83M | 2.04M | 216.00K | 9.00K | 2.00K |
| Interest Expense | 897.00K | 1.51M | 915.00K | 223.00K | 1.22M | 698.00K |
| Depreciation & Amortization | 615.95K | 571.32K | 343.45K | 105.72K | 80.98K | 73.93K |
| EBITDA | -21.40M | -22.58M | -24.17M | -16.46M | -11.90M | -6.18M |
| EBITDA Ratio | -29,319.18% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.20M | -25.26M | -25.83M | -16.57M | -10.86M | -5.63M |
| Operating Income Ratio | -30,406.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -718.00K | 1.32M | 1.12M | -7.00K | -1.16M | -636.93K |
| Income Before Tax | -22.92M | -23.94M | -24.71M | -16.58M | -12.02M | -6.27M |
| Income Before Tax Ratio | -31,390.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -791.22K | -772.00K | -178.00K | -1.56M | -825.00K | -735.00K |
| Net Income | -22.13M | -23.17M | -24.53M | -15.02M | -11.20M | -5.54M |
| Net Income Ratio | -30,308.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -8.11 | -9.80 | -12.58 | -9.27 | -6.91 | -2.88 |
| EPS Diluted | -8.11 | -9.80 | -12.58 | -9.27 | -6.91 | -2.88 |
| Weighted Avg Shares Out | 2.73M | 2.36M | 1.95M | 1.62M | 1.62M | 1.92M |
| Weighted Avg Shares Out (Dil) | 2.73M | 2.36M | 1.95M | 1.62M | 1.62M | 1.92M |
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
COPENHAGEN, Denmark, November 12, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new positive preclinical data from its ongoing cytomegalovirus (CMV) vaccine program named EVX-V1. The data will be...
Evaxion announces business update and third quarter 2024 financial results
COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2024 financial results.
Evaxion to announce business update and third quarter 2024 financial results on October 31
COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024,...
Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials
COPENHAGEN, Denmark, October 9, 2024 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has now evidence from three different clinical trials validating the vaccine target predictions of its AI platform.
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
COPENHAGEN, Denmark, October 3, 2024 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, continues to gather clinical evidence for the steady improvement of its AI-Immunology™ platform.
Evaxion significantly expands vaccine development collaboration with MSD
COPENHAGEN, Denmark, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it has entered into an option and license agreement with MSD (tradename of...
Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
COPENHAGEN, Denmark, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, launches an enhanced version of its clinically validated AI-Immunology™ platform with an update of its EDEN™...
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
COPENHAGEN, Denmark, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new pre-clinical data demonstrating the ability of its novel EVX-B2 mRNA Gonorrhea vaccine candidate in...
Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript
Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rono - Chief Scientific Officer Jesper Nissen - Chief Operating Officer and Chief Financial Officer Mads...
Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2024 financial results...
Source: https://incomestatements.info
Category: Stock Reports